首页 > 最新文献

Therapeutic Advances in Chronic Disease最新文献

英文 中文
Dynamic shifts in lung cytokine patterns in post-COVID-19 interstitial lung disease patients: a pilot study. COVID-19 后间质性肺病患者肺细胞因子模式的动态变化:一项试点研究。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-30 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241236257
Daniela Oatis, Hildegard Herman, Cornel Balta, Alina Ciceu, Erika Simon-Repolski, Alin Gabriel Mihu, Caterina Claudia Lepre, Marina Russo, Maria Consiglia Trotta, Antonietta Gerarda Gravina, Michele D'Amico, Anca Hermenean

Introduction: The pathogenesis of post-COVID interstitial lung disease, marked by lung tissue scarring and functional decline, remains largely unknown.

Objectives: We aimed to elucidate the temporal cytokine/chemokine changes in bronchoalveolar lavage (BAL) from patients with post-COVID interstitial lung disease to uncover potential immune drivers of pulmonary complications.

Design: We evaluated 16 females diagnosed with post-COVID interstitial lung disease, originating from moderate to severe cases during the second epidemic wave in the Autumn of 2020, treated at the Pneumology Department of the Arad County Clinical Hospital, Romania. Their inflammatory response over time was compared to a control group.

Methods: A total of 48 BAL samples were collected over three intervals (1, 3, and 6 months) and underwent cytology, gene, and protein expression analyses for pro/anti-inflammatory lung cytokines and chemokines using reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay.

Results: One month after infection, there were significant increases in the levels of IL-6 and IL-8. These levels decreased gradually over the course of 6 months but were still higher than those seen in control. Interferon-gamma and tumor necrosis factor alpha exhibited similar patterns. Persistent elevations were found in IL-10, IL-13, and pro-fibrotic M2 macrophages' chemokines (CCL13 and CCL18) for 6 months. Furthermore, pronounced neutrophilia was observed at 1 month post-COVID, highlighting persistent inflammation and lung damage. Neutrophil efferocytosis, aiding inflammation resolution and tissue repair, was evident at the 1-month time interval. A notable time-dependent reduction in CD28 was also noticed.

Conclusion: Our research provides insight into the immunological processes that may lead to the fibrotic changes noted in the lungs following COVID-19.

导言:COVID后间质性肺病以肺组织瘢痕形成和功能衰退为特征,其发病机制在很大程度上仍不清楚:目的:我们旨在阐明 COVID 后间质性肺疾病患者支气管肺泡灌洗液(BAL)中细胞因子/趋化因子的时间性变化,以发现肺部并发症的潜在免疫驱动因素:我们对罗马尼亚阿拉德县临床医院(Arad County Clinical Hospital)肺炎科诊治的 16 名确诊为后 COVID 间质性肺病的女性患者进行了评估,这些患者来自 2020 年秋季第二次疫情中的中度至重度病例。他们的炎症反应与对照组进行了比较:方法:在三个间隔期(1、3 和 6 个月)内共收集 48 份 BAL 样本,并使用反转录聚合酶链反应和酶联免疫吸附试验对促炎/抗炎肺细胞因子和趋化因子进行细胞学、基因和蛋白质表达分析:感染一个月后,IL-6 和 IL-8 的水平显著升高。这些水平在 6 个月内逐渐下降,但仍高于对照组。γ干扰素和肿瘤坏死因子α也表现出类似的模式。IL-10、IL-13 和促纤维化 M2 巨噬细胞趋化因子(CCL13 和 CCL18)在 6 个月内持续升高。此外,COVID 后 1 个月时观察到明显的中性粒细胞增多,突出显示了持续的炎症和肺损伤。中性粒细胞的排出有助于炎症的消退和组织的修复,在 1 个月的时间间隔内表现明显。此外,CD28的减少也与时间有关:我们的研究有助于深入了解可能导致 COVID-19 后肺部纤维化变化的免疫过程。
{"title":"Dynamic shifts in lung cytokine patterns in post-COVID-19 interstitial lung disease patients: a pilot study.","authors":"Daniela Oatis, Hildegard Herman, Cornel Balta, Alina Ciceu, Erika Simon-Repolski, Alin Gabriel Mihu, Caterina Claudia Lepre, Marina Russo, Maria Consiglia Trotta, Antonietta Gerarda Gravina, Michele D'Amico, Anca Hermenean","doi":"10.1177/20406223241236257","DOIUrl":"10.1177/20406223241236257","url":null,"abstract":"<p><strong>Introduction: </strong>The pathogenesis of post-COVID interstitial lung disease, marked by lung tissue scarring and functional decline, remains largely unknown.</p><p><strong>Objectives: </strong>We aimed to elucidate the temporal cytokine/chemokine changes in bronchoalveolar lavage (BAL) from patients with post-COVID interstitial lung disease to uncover potential immune drivers of pulmonary complications.</p><p><strong>Design: </strong>We evaluated 16 females diagnosed with post-COVID interstitial lung disease, originating from moderate to severe cases during the second epidemic wave in the Autumn of 2020, treated at the Pneumology Department of the Arad County Clinical Hospital, Romania. Their inflammatory response over time was compared to a control group.</p><p><strong>Methods: </strong>A total of 48 BAL samples were collected over three intervals (1, 3, and 6 months) and underwent cytology, gene, and protein expression analyses for pro/anti-inflammatory lung cytokines and chemokines using reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>One month after infection, there were significant increases in the levels of IL-6 and IL-8. These levels decreased gradually over the course of 6 months but were still higher than those seen in control. Interferon-gamma and tumor necrosis factor alpha exhibited similar patterns. Persistent elevations were found in IL-10, IL-13, and pro-fibrotic M2 macrophages' chemokines (CCL13 and CCL18) for 6 months. Furthermore, pronounced neutrophilia was observed at 1 month post-COVID, highlighting persistent inflammation and lung damage. Neutrophil efferocytosis, aiding inflammation resolution and tissue repair, was evident at the 1-month time interval. A notable time-dependent reduction in CD28 was also noticed.</p><p><strong>Conclusion: </strong>Our research provides insight into the immunological processes that may lead to the fibrotic changes noted in the lungs following COVID-19.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241236257"},"PeriodicalIF":3.5,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain functional and structural changes in diabetic children. How can intellectual development be optimized in type 1 diabetes? 糖尿病儿童大脑功能和结构的变化。如何优化 1 型糖尿病患者的智力发育?
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-29 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241229855
Maia Stanisławska-Kubiak, Katarzyna Anna Majewska, Agata Krasińska, Paulina Wais, Dominik Majewski, Ewa Mojs, Andrzej Kȩdzia

The neuropsychological functioning of people with type 1 diabetes (T1D) is of key importance to the effectiveness of the therapy, which, in its complexity, requires a great deal of knowledge, attention, and commitment. Intellectual limitations make it difficult to achieve the optimal metabolic balance, and a lack of this alignment can contribute to the further deterioration of cognitive functions. The aim of this study was to provide a narrative review of the current state of knowledge regarding the influence of diabetes on brain structure and functions during childhood and also to present possible actions to optimize intellectual development in children with T1D. Scopus, PubMed, and Web of Science databases were searched for relevant literature using selected keywords. The results were summarized using a narrative synthesis. Disturbances in glucose metabolism during childhood may have a lasting negative effect on the development of the brain and related cognitive functions. To optimize intellectual development in children with diabetes, it is essential to prevent disorders of the central nervous system by maintaining peri-normal glycemic levels. Based on the performed literature review, it seems necessary to take additional actions, including repeated neuropsychological evaluation with early detection of any cognitive dysfunctions, followed by the development of individual management strategies and the training of appropriate skills, together with complex, multidirectional environmental support.

1 型糖尿病(T1D)患者的神经心理功能对治疗效果至关重要,而治疗的复杂性需要大量的知识、关注和投入。智力上的限制使其很难达到最佳的代谢平衡,而缺乏这种平衡会导致认知功能进一步恶化。本研究旨在对糖尿病对儿童期大脑结构和功能的影响的现有知识进行叙述性回顾,并提出优化 T1D 儿童智力发育的可能措施。我们使用选定的关键词在 Scopus、PubMed 和 Web of Science 数据库中搜索了相关文献。研究结果采用叙事综合法进行总结。儿童时期葡萄糖代谢紊乱可能会对大脑发育和相关认知功能产生持久的负面影响。为了优化儿童糖尿病患者的智力发育,必须通过维持近正常血糖水平来预防中枢神经系统紊乱。根据已完成的文献综述,似乎有必要采取额外的行动,包括反复进行神经心理学评估,及早发现任何认知功能障碍,然后制定个人管理策略,进行适当的技能培训,同时提供复杂的、多方位的环境支持。
{"title":"Brain functional and structural changes in diabetic children. How can intellectual development be optimized in type 1 diabetes?","authors":"Maia Stanisławska-Kubiak, Katarzyna Anna Majewska, Agata Krasińska, Paulina Wais, Dominik Majewski, Ewa Mojs, Andrzej Kȩdzia","doi":"10.1177/20406223241229855","DOIUrl":"10.1177/20406223241229855","url":null,"abstract":"<p><p>The neuropsychological functioning of people with type 1 diabetes (T1D) is of key importance to the effectiveness of the therapy, which, in its complexity, requires a great deal of knowledge, attention, and commitment. Intellectual limitations make it difficult to achieve the optimal metabolic balance, and a lack of this alignment can contribute to the further deterioration of cognitive functions. The aim of this study was to provide a narrative review of the current state of knowledge regarding the influence of diabetes on brain structure and functions during childhood and also to present possible actions to optimize intellectual development in children with T1D. Scopus, PubMed, and Web of Science databases were searched for relevant literature using selected keywords. The results were summarized using a narrative synthesis. Disturbances in glucose metabolism during childhood may have a lasting negative effect on the development of the brain and related cognitive functions. To optimize intellectual development in children with diabetes, it is essential to prevent disorders of the central nervous system by maintaining peri-normal glycemic levels. Based on the performed literature review, it seems necessary to take additional actions, including repeated neuropsychological evaluation with early detection of any cognitive dysfunctions, followed by the development of individual management strategies and the training of appropriate skills, together with complex, multidirectional environmental support.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241229855"},"PeriodicalIF":3.5,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study. 巨细胞病毒对急性重度溃疡性结肠炎预后的影响:一项回顾性观察研究。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-28 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241233203
Dazhong Huang, Michael Rennie, Alicia Krasovec, Shyam Nagubandi, Sichang Liu, Edward Ge, Barinder Khehra, Michael Au, Shobini Sivagnanam, Vu Kwan, Claudia Rogge, Nikola Mitrev, Viraj Kariyawasam

Background: Concomitant cytomegalovirus (CMV) is highly prevalent in acute severe ulcerative colitis (ASUC) but data for outcomes of CMV positivity in ASUC and the benefit of antiviral therapy remain unclear.

Objectives: We aim to determine the impact of CMV positivity, and antiviral therapy, on outcomes such as colectomy-free survival, length of hospital stay and readmission rate, among hospitalized patients with ASUC.

Design: This is a retrospective, multicentre study of patients admitted with ASUC.

Methods: CMV positivity was diagnosed from blood CMV DNA and inpatient colonic biopsies. Background demographics and disease characteristics, clinical characteristics and outcomes during admission and long-term outcomes were obtained from electronic medical records and compared according to the presence of CMV and the use of antiviral therapy.

Results: CMV was detected in 40 (24%) of 167 ASUC admissions. Previous steroid exposure was the only clinical predictor of CMV positivity on multivariate analysis. Outcomes of greater requirement for rescue therapy (60% versus 33%), longer hospital stay (14.3 versus 9.9 days) and higher readmission rates at 3 and 12 months were associated with CMV positivity. No difference was found in the rate of colectomy or colectomy-free survival. Antiviral therapy was not associated with a lower risk of colectomy but did extend the time to colectomy (126 versus 36 days).

Conclusion: CMV positivity was associated with worse outcomes of need for rescue therapy, hospital stay and readmissions. Antiviral therapy was not found to reduce the risk of colectomy but did extend the time to colectomy. Further prospective studies will be required to more clearly determine its benefit in patients with concomitant CMV and ASUC.

背景:合并巨细胞病毒(CMV)在急性重症溃疡性结肠炎(ASUC)中的发病率很高,但ASUC中CMV阳性患者的预后数据以及抗病毒治疗的益处仍不清楚:我们旨在确定CMV阳性和抗病毒治疗对急性重症溃疡性结肠炎住院患者无结肠切除术生存率、住院时间和再入院率等结果的影响:这是一项针对ASUC住院患者的多中心回顾性研究:方法:根据血液中的 CMV DNA 和住院患者结肠活检结果确诊 CMV 阳性。从电子病历中获取背景人口统计学资料和疾病特征、入院时的临床特征和预后以及长期预后,并根据CMV的存在和抗病毒治疗的使用情况进行比较:结果:在167例ASUC入院患者中,有40例(24%)检测出CMV。在多变量分析中,既往类固醇暴露是CMV阳性的唯一临床预测因素。CMV阳性患者需要更多的抢救治疗(60%对33%),住院时间更长(14.3天对9.9天),3个月和12个月后的再入院率更高。结肠切除率和无结肠切除生存率没有差异。抗病毒治疗与结肠切除术风险降低无关,但确实延长了结肠切除术的时间(126天对36天):结论:CMV 阳性与需要抢救治疗、住院和再入院等不良后果有关。抗病毒治疗并未降低结肠切除术的风险,但却延长了结肠切除术的时间。需要进一步开展前瞻性研究,以更明确地确定抗病毒治疗对合并 CMV 和 ASUC 患者的益处。
{"title":"Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study.","authors":"Dazhong Huang, Michael Rennie, Alicia Krasovec, Shyam Nagubandi, Sichang Liu, Edward Ge, Barinder Khehra, Michael Au, Shobini Sivagnanam, Vu Kwan, Claudia Rogge, Nikola Mitrev, Viraj Kariyawasam","doi":"10.1177/20406223241233203","DOIUrl":"10.1177/20406223241233203","url":null,"abstract":"<p><strong>Background: </strong>Concomitant cytomegalovirus (CMV) is highly prevalent in acute severe ulcerative colitis (ASUC) but data for outcomes of CMV positivity in ASUC and the benefit of antiviral therapy remain unclear.</p><p><strong>Objectives: </strong>We aim to determine the impact of CMV positivity, and antiviral therapy, on outcomes such as colectomy-free survival, length of hospital stay and readmission rate, among hospitalized patients with ASUC.</p><p><strong>Design: </strong>This is a retrospective, multicentre study of patients admitted with ASUC.</p><p><strong>Methods: </strong>CMV positivity was diagnosed from blood CMV DNA and inpatient colonic biopsies. Background demographics and disease characteristics, clinical characteristics and outcomes during admission and long-term outcomes were obtained from electronic medical records and compared according to the presence of CMV and the use of antiviral therapy.</p><p><strong>Results: </strong>CMV was detected in 40 (24%) of 167 ASUC admissions. Previous steroid exposure was the only clinical predictor of CMV positivity on multivariate analysis. Outcomes of greater requirement for rescue therapy (60% <i>versus</i> 33%), longer hospital stay (14.3 <i>versus</i> 9.9 days) and higher readmission rates at 3 and 12 months were associated with CMV positivity. No difference was found in the rate of colectomy or colectomy-free survival. Antiviral therapy was not associated with a lower risk of colectomy but did extend the time to colectomy (126 <i>versus</i> 36 days).</p><p><strong>Conclusion: </strong>CMV positivity was associated with worse outcomes of need for rescue therapy, hospital stay and readmissions. Antiviral therapy was not found to reduce the risk of colectomy but did extend the time to colectomy. Further prospective studies will be required to more clearly determine its benefit in patients with concomitant CMV and ASUC.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241233203"},"PeriodicalIF":3.5,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation. 患者对活动性溃疡性结肠炎治疗和粪便微生物群移植的偏好。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-26 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241239168
Deborah A Marshall, Karen V MacDonald, Dina Kao, Charles N Bernstein, Gilaad G Kaplan, Humberto Jijon, Glen Hazlewood, Remo Panaccione, Yasmin Nasser, Maitreyi Raman, Paul Moayyedi

Background: Fecal microbiota transplantation (FMT) is a promising treatment for active ulcerative colitis (UC). Understanding patient preferences can identify treatment features that may impact treatment decisions, improve shared decision-making, and contribute to patient-centered care, which is especially important in the context of novel treatments like FMT.

Objectives: We aimed to quantify preferences for active UC treatments, specifically FMT and biologics, and identify patient characteristics associated with different preference patterns.

Design: This is a cross-sectional survey study.

Methods: We administered a discrete choice experiment (DCE) survey to elicit preferences in a sample of Canadian adults with UC. DCE data were analyzed using a main-effects mixed logit model and used to predict uptake of hypothetical scenarios reflecting alternative combinations of treatment features. Latent class modeling identified heterogeneity in patient preference patterns.

Results: Participants' (n = 201) mean age was 47.1 years (SD: 14.5 years), 58% were female, and most (84%) had at least some post-secondary education. Almost half were willing to undergo FMT. When considering treatments for active UC, the most important attributes were chance of remission and severity of rare unknown side effects. All else equal, participants were most likely to uptake treatment that involves oral capsules/pills. Participants in the class with the highest utility for chance of remission were younger, had more severe disease, and 58% indicated that they would be willing to undergo FMT.

Conclusion: We identified characteristics of UC patients who are more likely to be interested in FMT using preference elicitation methods. Patient-centered care can be enhanced by knowing which patients are more likely to be interested in FMT, potentially improving satisfaction with and adherence to treatments for active UC to maximize the effectiveness of treatment while considering heterogeneity in patient preferences.

背景:粪便微生物群移植(FMT)是治疗活动性溃疡性结肠炎(UC)的一种很有前景的方法。了解患者的偏好可以确定可能影响治疗决策的治疗特点,改善共同决策,并促进以患者为中心的护理,这对于 FMT 等新型疗法尤为重要:我们旨在量化患者对积极的 UC 治疗(尤其是 FMT 和生物制剂)的偏好,并识别与不同偏好模式相关的患者特征:这是一项横断面调查研究:我们对加拿大成年 UC 患者进行了离散选择实验(DCE)调查,以了解他们的偏好。我们使用主效应混合对数模型对离散选择实验数据进行了分析,并用它来预测对反映治疗特征替代组合的假设情景的接受程度。潜类模型确定了患者偏好模式的异质性:参与者(n = 201)的平均年龄为 47.1 岁(SD:14.5 岁),58% 为女性,大多数(84%)至少受过高等教育。近一半的人愿意接受 FMT 治疗。在考虑活动性 UC 的治疗方法时,最重要的因素是缓解的几率和罕见未知副作用的严重程度。在其他条件相同的情况下,参与者最有可能接受口服胶囊/药片的治疗。对病情缓解几率效用最高的那一类参与者更年轻,病情更严重,58%的人表示愿意接受FMT治疗:结论:我们利用偏好激发方法确定了更有可能对 FMT 感兴趣的 UC 患者的特征。通过了解哪些患者更有可能对 FMT 感兴趣,可以加强以患者为中心的护理,从而有可能提高活动性 UC 治疗的满意度和依从性,在考虑患者偏好异质性的同时最大限度地提高治疗效果。
{"title":"Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.","authors":"Deborah A Marshall, Karen V MacDonald, Dina Kao, Charles N Bernstein, Gilaad G Kaplan, Humberto Jijon, Glen Hazlewood, Remo Panaccione, Yasmin Nasser, Maitreyi Raman, Paul Moayyedi","doi":"10.1177/20406223241239168","DOIUrl":"10.1177/20406223241239168","url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota transplantation (FMT) is a promising treatment for active ulcerative colitis (UC). Understanding patient preferences can identify treatment features that may impact treatment decisions, improve shared decision-making, and contribute to patient-centered care, which is especially important in the context of novel treatments like FMT.</p><p><strong>Objectives: </strong>We aimed to quantify preferences for active UC treatments, specifically FMT and biologics, and identify patient characteristics associated with different preference patterns.</p><p><strong>Design: </strong>This is a cross-sectional survey study.</p><p><strong>Methods: </strong>We administered a discrete choice experiment (DCE) survey to elicit preferences in a sample of Canadian adults with UC. DCE data were analyzed using a main-effects mixed logit model and used to predict uptake of hypothetical scenarios reflecting alternative combinations of treatment features. Latent class modeling identified heterogeneity in patient preference patterns.</p><p><strong>Results: </strong>Participants' (<i>n</i> = 201) mean age was 47.1 years (SD: 14.5 years), 58% were female, and most (84%) had at least some post-secondary education. Almost half were willing to undergo FMT. When considering treatments for active UC, the most important attributes were chance of remission and severity of rare unknown side effects. All else equal, participants were most likely to uptake treatment that involves oral capsules/pills. Participants in the class with the highest utility for chance of remission were younger, had more severe disease, and 58% indicated that they would be willing to undergo FMT.</p><p><strong>Conclusion: </strong>We identified characteristics of UC patients who are more likely to be interested in FMT using preference elicitation methods. Patient-centered care can be enhanced by knowing which patients are more likely to be interested in FMT, potentially improving satisfaction with and adherence to treatments for active UC to maximize the effectiveness of treatment while considering heterogeneity in patient preferences.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241239168"},"PeriodicalIF":3.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10966996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis. 原发性醛固酮增多症不同医疗方法的比较:系统综述和网络荟萃分析。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-19 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241239775
Wen-Yu Ho, Ching-Chung Hsiao, Ping-Hsun Wu, Jui-Yi Chen, Yu-Kang Tu, Vin-Cent Wu, Jia-Jin Chen

Background: The effectiveness and side effects between different medical treatments in patients with primary hyperaldosteronism have not been systematically studied.

Objective: To analyze the efficacy between different mineralocorticoid receptor antagonists (MRAs) and epithelial sodium channel (ENaC) inhibitors in a network meta-analysis (NMA) framework, while also evaluating adverse events.

Design: Systematic review and NMA.

Data sources and methods: The systematic review and NMA was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, MEDLINE, the Cochrane library, and Excerpta Medica database (EMBASE) were searched for randomized controlled trials (RCTs) involving adult patients with primary hyperaldosteronism until 23 June 2023. Studies that compared the efficacy and side effects of different medical treatments of primary hyperaldosteronism were included. The primary outcomes included the effect on blood pressure, serum potassium, and major adverse cardiovascular events. The secondary outcomes were adverse events related to MRAs (hyperkalemia and gynecomastia). Frequentist NMA and pairwise meta-analysis were conducted.

Results: A total of 5 RCTs comprising 392 participants were included. Eplerenone, esaxerenone, and amiloride were compared to spironolactone and demonstrated comparable effect on the reduction of systolic blood pressure. In comparison to spironolactone, eplerenone exhibited a less pronounced effect on reducing diastolic blood pressure [-4.63 mmHg; 95% confidence interval (CI): -8.87 to -0.40 mmHg] and correcting serum potassium (-0.2 mg/dL; 95% CI: -0.37 to -0.03 mg/dL). Spironolactone presented a higher risk of gynecomastia compared with eplerenone (relative risk: 4.69; 95% CI: 3.58-6.14).

Conclusion: The present NMA indicated that the blood pressure reduction and potassium-correcting effects of the three MRAs may demonstrate marginal differences, with confidence levels in the evidence being very low. Therefore, further research is needed to explore the efficacy of these MRAs, especially regarding their impact on mortality and cardiovascular outcomes.

Trial registration: PROSPERO (CRD: 42023446811).

背景:原发性高醛固酮症患者接受不同药物治疗的效果和副作用尚未得到系统研究:原发性高醛固酮症患者接受不同药物治疗的疗效和副作用尚未得到系统研究:在网络荟萃分析(NMA)框架下分析不同矿皮质激素受体拮抗剂(MRA)和上皮钠通道(ENaC)抑制剂之间的疗效,同时评估不良反应:数据来源和方法:系统综述和 NMA 根据《系统综述和荟萃分析首选报告项目》指南进行报告。检索了 PubMed、MEDLINE、Cochrane 图书馆和 Excerpta Medica 数据库 (EMBASE) 中截至 2023 年 6 月 23 日涉及原发性醛固酮增多症成人患者的随机对照试验 (RCT)。纳入的研究比较了原发性高醛固酮症不同医疗方法的疗效和副作用。主要结果包括对血压、血清钾和主要心血管不良事件的影响。次要结果是与 MRAs 相关的不良事件(高血钾和妇科炎症)。研究进行了频数NMA和配对荟萃分析:结果:共纳入了 5 项 RCT,共有 392 名参与者。将依普利酮、艾司西酮和氨苯蝶啶与螺内酯进行了比较,结果显示它们在降低收缩压方面的效果相当。与螺内酯相比,依普利酮在降低舒张压[-4.63 mmHg;95% 置信区间(CI):-8.87 至 -0.40 mmHg]和纠正血清钾(-0.2 mg/dL;95% CI:-0.37 至 -0.03 mg/dL)方面的效果不明显。与依普利酮相比,螺内酯导致妇科肿瘤的风险更高(相对风险:4.69;95% CI:3.58-6.14):本 NMA 研究表明,三种 MRA 的降压和血钾纠正效果可能存在微小差异,证据的置信度非常低。因此,需要进一步研究这些 MRA 的疗效,尤其是它们对死亡率和心血管后果的影响:试验注册:prospero(CRD:42023446811)。
{"title":"Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis.","authors":"Wen-Yu Ho, Ching-Chung Hsiao, Ping-Hsun Wu, Jui-Yi Chen, Yu-Kang Tu, Vin-Cent Wu, Jia-Jin Chen","doi":"10.1177/20406223241239775","DOIUrl":"10.1177/20406223241239775","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness and side effects between different medical treatments in patients with primary hyperaldosteronism have not been systematically studied.</p><p><strong>Objective: </strong>To analyze the efficacy between different mineralocorticoid receptor antagonists (MRAs) and epithelial sodium channel (ENaC) inhibitors in a network meta-analysis (NMA) framework, while also evaluating adverse events.</p><p><strong>Design: </strong>Systematic review and NMA.</p><p><strong>Data sources and methods: </strong>The systematic review and NMA was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, MEDLINE, the Cochrane library, and Excerpta Medica database (EMBASE) were searched for randomized controlled trials (RCTs) involving adult patients with primary hyperaldosteronism until 23 June 2023. Studies that compared the efficacy and side effects of different medical treatments of primary hyperaldosteronism were included. The primary outcomes included the effect on blood pressure, serum potassium, and major adverse cardiovascular events. The secondary outcomes were adverse events related to MRAs (hyperkalemia and gynecomastia). Frequentist NMA and pairwise meta-analysis were conducted.</p><p><strong>Results: </strong>A total of 5 RCTs comprising 392 participants were included. Eplerenone, esaxerenone, and amiloride were compared to spironolactone and demonstrated comparable effect on the reduction of systolic blood pressure. In comparison to spironolactone, eplerenone exhibited a less pronounced effect on reducing diastolic blood pressure [-4.63 mmHg; 95% confidence interval (CI): -8.87 to -0.40 mmHg] and correcting serum potassium (-0.2 mg/dL; 95% CI: -0.37 to -0.03 mg/dL). Spironolactone presented a higher risk of gynecomastia compared with eplerenone (relative risk: 4.69; 95% CI: 3.58-6.14).</p><p><strong>Conclusion: </strong>The present NMA indicated that the blood pressure reduction and potassium-correcting effects of the three MRAs may demonstrate marginal differences, with confidence levels in the evidence being very low. Therefore, further research is needed to explore the efficacy of these MRAs, especially regarding their impact on mortality and cardiovascular outcomes.</p><p><strong>Trial registration: </strong>PROSPERO (CRD: 42023446811).</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241239775"},"PeriodicalIF":3.5,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of seizure outcomes in stereo-electroencephalography-guided radio-frequency thermocoagulation for MRI-negative epilepsy. 立体脑电图引导下射频热凝治疗核磁共振阴性癫痫的癫痫发作预后。
IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-15 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241236258
Qi Huang, Pandeng Xie, Jian Zhou, Haoran Ding, Zhao Liu, Tianfu Li, Yuguang Guan, Mengyang Wang, Jing Wang, Pengfei Teng, Mingwang Zhu, Kaiqiang Ma, Han Wu, Guoming Luan, Feng Zhai

Background: One-third of intractable epilepsy patients have no visually identifiable focus for neurosurgery based on imaging tests [magnetic resonance imaging (MRI)-negative cases]. Stereo-electroencephalography-guided radio-frequency thermocoagulation (SEEG-guided RF-TC) is utilized in the clinical treatment of epilepsy to lower the incidence of complications post-open surgery.

Objective: This study aimed to identify prognostic factors and long-term seizure outcomes in SEEG-guided RF-TC for patients with MRI-negative epilepsy.

Design: This was a single-center retrospective cohort study.

Methods: We included 30 patients who had undergone SEEG-guided RF-TC at Sanbo Brain Hospital, Capital Medical University, from April 2015 to December 2019. The probability of remaining seizure-free and the plotted survival curves were analyzed. Prognostic factors were analyzed using log-rank tests in univariate analysis and the Cox regression model in multivariate analysis.

Results: With a mean time of 31.07 ± 2.64 months (median 30.00, interquartile range: 18.00-40.00 months), 11 out of 30 patients (36.7%) were classified as International League Against Epilepsy class 1 in the last follow-up. The mean time of remaining seizure-free was 21.33 ± 4.55 months [95% confidence interval (CI) 12.41-30.25], and the median time was 3.00 ± 0.54 months (95% CI 1.94-4.06). Despite falling in the initial year, the probability of remaining seizure-free gradually stabilizes in the subsequent years. The patients were more likely to obtain seizure freedom when the epileptogenic zone was located in the insular lobe or with one focus on the limbic system (p = 0.034, hazard ratio 5.019, 95% CI 1.125-22.387).

Conclusion: Our findings may be applied to guide individualized surgical interventions and help clinicians make better decisions.

背景:三分之一的难治性癫痫患者根据影像学检查无法肉眼识别神经外科手术病灶[磁共振成像(MRI)阴性病例]。立体脑电图引导下射频热凝术(SEEG-guided RF-TC)被用于癫痫的临床治疗,以降低开颅手术后并发症的发生率:本研究旨在确定磁共振成像阴性癫痫患者在SEEG引导下进行RF-TC治疗的预后因素和长期发作结果:这是一项单中心回顾性队列研究:纳入2015年4月至2019年12月在首都医科大学三博脑科医院接受SEEG引导下RF-TC治疗的30例患者。分析了无癫痫发作的概率和绘制的生存曲线。在单变量分析中使用对数秩检验,在多变量分析中使用 Cox 回归模型分析预后因素:30例患者中,有11例(36.7%)在最后一次随访中被归类为国际抗癫痫联盟1级,平均随访时间为(31.07±2.64)个月(中位数为30.00个月,四分位数范围为18.00-40.00个月)。无癫痫发作的平均时间为(21.33 ± 4.55)个月[95% 置信区间(CI)12.41-30.25],中位时间为(3.00 ± 0.54)个月(95% CI 1.94-4.06)。尽管在最初的一年中癫痫发作概率有所下降,但在随后的几年中,癫痫不再发作的概率逐渐趋于稳定。致痫区位于岛叶或病灶位于边缘系统时,患者更有可能摆脱癫痫发作(P = 0.034,危险比 5.019,95% CI 1.125-22.387):我们的研究结果可用于指导个体化手术干预,帮助临床医生做出更好的决定。
{"title":"Predictors of seizure outcomes in stereo-electroencephalography-guided radio-frequency thermocoagulation for MRI-negative epilepsy.","authors":"Qi Huang, Pandeng Xie, Jian Zhou, Haoran Ding, Zhao Liu, Tianfu Li, Yuguang Guan, Mengyang Wang, Jing Wang, Pengfei Teng, Mingwang Zhu, Kaiqiang Ma, Han Wu, Guoming Luan, Feng Zhai","doi":"10.1177/20406223241236258","DOIUrl":"10.1177/20406223241236258","url":null,"abstract":"<p><strong>Background: </strong>One-third of intractable epilepsy patients have no visually identifiable focus for neurosurgery based on imaging tests [magnetic resonance imaging (MRI)-negative cases]. Stereo-electroencephalography-guided radio-frequency thermocoagulation (SEEG-guided RF-TC) is utilized in the clinical treatment of epilepsy to lower the incidence of complications post-open surgery.</p><p><strong>Objective: </strong>This study aimed to identify prognostic factors and long-term seizure outcomes in SEEG-guided RF-TC for patients with MRI-negative epilepsy.</p><p><strong>Design: </strong>This was a single-center retrospective cohort study.</p><p><strong>Methods: </strong>We included 30 patients who had undergone SEEG-guided RF-TC at Sanbo Brain Hospital, Capital Medical University, from April 2015 to December 2019. The probability of remaining seizure-free and the plotted survival curves were analyzed. Prognostic factors were analyzed using log-rank tests in univariate analysis and the Cox regression model in multivariate analysis.</p><p><strong>Results: </strong>With a mean time of 31.07 ± 2.64 months (median 30.00, interquartile range: 18.00-40.00 months), 11 out of 30 patients (36.7%) were classified as International League Against Epilepsy class 1 in the last follow-up. The mean time of remaining seizure-free was 21.33 ± 4.55 months [95% confidence interval (CI) 12.41-30.25], and the median time was 3.00 ± 0.54 months (95% CI 1.94-4.06). Despite falling in the initial year, the probability of remaining seizure-free gradually stabilizes in the subsequent years. The patients were more likely to obtain seizure freedom when the epileptogenic zone was located in the insular lobe or with one focus on the limbic system (<i>p</i> = 0.034, hazard ratio 5.019, 95% CI 1.125-22.387).</p><p><strong>Conclusion: </strong>Our findings may be applied to guide individualized surgical interventions and help clinicians make better decisions.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241236258"},"PeriodicalIF":3.3,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10943718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Photodynamic therapy of cervical cancer: a scoping review on the efficacy of various molecules. 宫颈癌的光动力疗法:各种分子疗效的范围综述。
IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-04 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241233206
Nasrulla Abdullaevich Shanazarov, Afshin Zare, Nadiar Maratovich Mussin, Rustam Kuanyshbekovich Albayev, Asset Askerovich Kaliyev, Yerbolat Maratovich Iztleuov, Sandugash Bakhytbekovna Smailova, Amin Tamadon

Background: Cervical cancer poses a considerable worldwide health issue, where infection with the human papillomavirus (HPV) plays a vital role as a risk factor. Photodynamic therapy (PDT) is a minimally invasive treatment for HPV-related cervical lesions, which uses photosensitizers and light to selectively destroy abnormal cells.

Objectives: Our objective is to present a comprehensive overview of the different types of molecules employed in PDT to reduce the occurrence and fatality rates associated with cervical cancer.

Design: Scoping review and bibliometric analysis.

Methods: The article explores clinical trials investigating the efficacy of PDT in treating low-grade squamous intraepithelial lesion and high-grade squamous intraepithelial lesion, as well as preclinical approaches utilizing various molecules for PDT in cervical cancer. Furthermore, the article sheds light on potential molecules for PDT enhancement, examining their properties through computer modeling simulations, molecular docking, and assessing their advantages and disadvantages.

Results: Our findings demonstrate that PDT holds promise as a therapeutic approach for treating cervical lesions associated with HPV and cervical cancer. Additionally, we observe that the utilization of diverse dye classes enhances the anticancer effects of PDT.

Conclusion: Among the various molecules employed in PDT, functionalized fullerene exhibits a notable inclination toward overexpressed receptors in cervical cancer cells, making it a potential candidate for intensified use in PDT. However, further research is needed to evaluate its long-term effectiveness and safety.

背景:宫颈癌是一个严重的世界性健康问题,而感染人类乳头瘤病毒(HPV)是其中一个重要的危险因素。光动力疗法(PDT)是一种治疗 HPV 相关宫颈病变的微创疗法,它利用光敏剂和光来选择性地破坏异常细胞:我们的目标是全面概述在 PDT 中使用的不同类型的分子,以降低与宫颈癌相关的发生率和死亡率:设计:范围综述和文献计量分析:文章探讨了研究PDT治疗低级别鳞状上皮内病变和高级别鳞状上皮内病变疗效的临床试验,以及利用各种分子进行PDT治疗宫颈癌的临床前方法。此外,文章还通过计算机建模模拟、分子对接和评估其优缺点,研究了潜在的光动力疗法增强分子的特性:结果:我们的研究结果表明,光导光疗有望成为治疗与人乳头瘤病毒和宫颈癌相关的宫颈病变的一种治疗方法。此外,我们还观察到,使用不同类别的染料可增强光动力疗法的抗癌效果:结论:在光透射疗法中使用的各种分子中,功能化富勒烯对宫颈癌细胞中过表达的受体有明显的倾向性,使其成为光透射疗法中强化使用的潜在候选分子。不过,还需要进一步的研究来评估其长期有效性和安全性。
{"title":"Photodynamic therapy of cervical cancer: a scoping review on the efficacy of various molecules.","authors":"Nasrulla Abdullaevich Shanazarov, Afshin Zare, Nadiar Maratovich Mussin, Rustam Kuanyshbekovich Albayev, Asset Askerovich Kaliyev, Yerbolat Maratovich Iztleuov, Sandugash Bakhytbekovna Smailova, Amin Tamadon","doi":"10.1177/20406223241233206","DOIUrl":"10.1177/20406223241233206","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer poses a considerable worldwide health issue, where infection with the human papillomavirus (HPV) plays a vital role as a risk factor. Photodynamic therapy (PDT) is a minimally invasive treatment for HPV-related cervical lesions, which uses photosensitizers and light to selectively destroy abnormal cells.</p><p><strong>Objectives: </strong>Our objective is to present a comprehensive overview of the different types of molecules employed in PDT to reduce the occurrence and fatality rates associated with cervical cancer.</p><p><strong>Design: </strong>Scoping review and bibliometric analysis.</p><p><strong>Methods: </strong>The article explores clinical trials investigating the efficacy of PDT in treating low-grade squamous intraepithelial lesion and high-grade squamous intraepithelial lesion, as well as preclinical approaches utilizing various molecules for PDT in cervical cancer. Furthermore, the article sheds light on potential molecules for PDT enhancement, examining their properties through computer modeling simulations, molecular docking, and assessing their advantages and disadvantages.</p><p><strong>Results: </strong>Our findings demonstrate that PDT holds promise as a therapeutic approach for treating cervical lesions associated with HPV and cervical cancer. Additionally, we observe that the utilization of diverse dye classes enhances the anticancer effects of PDT.</p><p><strong>Conclusion: </strong>Among the various molecules employed in PDT, functionalized fullerene exhibits a notable inclination toward overexpressed receptors in cervical cancer cells, making it a potential candidate for intensified use in PDT. However, further research is needed to evaluate its long-term effectiveness and safety.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241233206"},"PeriodicalIF":3.3,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10910886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea secukinumab 对中重度斑块状银屑病成年患者的实际安全性和有效性:韩国上市后监测结果
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-26 DOI: 10.1177/20406223241230180
Byung Soo Kim, Dong Hyun Kim, Bong Seok Shin, Eun-So Lee, Seong Jin Jo, Chul Hwan Bang, Yeojun Yun, Yong Beom Choe
Background:Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015.Objectives:To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea.Design:Multicenter, real-world, noninterventional study conducted over 6 years.Methods:Adults with moderate to severe psoriasis were enrolled. Safety was assessed by evaluating adverse events (AEs), treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24.Results:Overall, 829 and 542 patients were included in the safety and effectiveness sets, respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient years, respectively. The absolute PASI score decreased from 16.1 ± 7.1 (baseline) to 1.6 ± 2.4 (week 24), with a similar reduction in biologic-naïve (16.4 ± 7.3 to 1.5 ± 2.2) and biologic-experienced (14.8 ± 5.9 to 2.4 ± 3.2) groups. At week 24, PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, PASI 75/90 were higher in biologic-naïve (96.6%/65.8%) than biologic-experienced patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts.Conclusion:Secukinumab showed sustained effectiveness and favorable safety profile in adult patients with moderate to severe psoriasis in Korea.
背景:赛库单抗是一种全人源单克隆抗体,2015年9月在韩国获批用于治疗中重度银屑病。目的:评估赛库单抗在韩国中重度银屑病患者中的安全性和有效性。设计:多中心、真实世界、非干预性研究,历时6年。方法:招募中重度银屑病成人患者。安全性通过评估不良事件(AEs)、治疗相关AEs和严重AEs(SAEs)进行评估。疗效通过第12周和第24周时银屑病面积和严重程度指数(PASI)绝对值的变化、达到PASI 75/90/100和PASI ⩽2的患者比例进行评估。29.0%、9.5%和4.1%的患者发生了AEs、治疗相关AEs和SAEs,发生率分别为每100例患者年39.43例、12.98例和5.59例。PASI绝对值从16.1±7.1(基线)降至1.6±2.4(第24周),生物制剂无效组(16.4±7.3降至1.5±2.2)和生物制剂经验组(14.8±5.9降至2.4±3.2)的降幅相似。第24周时,分别有95.1%、62.4%和24.9%的患者PASI达到75/90/100。第24周时,未使用过生物制剂的患者的PASI 75/90(96.6%/65.8%)高于使用过生物制剂的患者(88.3%/48.6%),而两组患者的PASI 100相似(24.1%和28.6%)。结论:在韩国,塞库单抗对中重度银屑病成年患者显示出持续的有效性和良好的安全性。
{"title":"Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea","authors":"Byung Soo Kim, Dong Hyun Kim, Bong Seok Shin, Eun-So Lee, Seong Jin Jo, Chul Hwan Bang, Yeojun Yun, Yong Beom Choe","doi":"10.1177/20406223241230180","DOIUrl":"https://doi.org/10.1177/20406223241230180","url":null,"abstract":"Background:Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015.Objectives:To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea.Design:Multicenter, real-world, noninterventional study conducted over 6 years.Methods:Adults with moderate to severe psoriasis were enrolled. Safety was assessed by evaluating adverse events (AEs), treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24.Results:Overall, 829 and 542 patients were included in the safety and effectiveness sets, respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient years, respectively. The absolute PASI score decreased from 16.1 ± 7.1 (baseline) to 1.6 ± 2.4 (week 24), with a similar reduction in biologic-naïve (16.4 ± 7.3 to 1.5 ± 2.2) and biologic-experienced (14.8 ± 5.9 to 2.4 ± 3.2) groups. At week 24, PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, PASI 75/90 were higher in biologic-naïve (96.6%/65.8%) than biologic-experienced patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts.Conclusion:Secukinumab showed sustained effectiveness and favorable safety profile in adult patients with moderate to severe psoriasis in Korea.","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"1 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139980977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and imaging findings in enteropathic spondyloarthritis with special emphasize in diagnostic delay: a cross-sectional study. 一项横断面研究:肠病性脊柱关节炎的临床和影像学发现,特别强调诊断延迟。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-19 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241229843
Paola Conigliaro, Arianna D'Antonio, Andrea Wlderk, Federico Sabuzi, Mario Ferraioli, Leonardo Sichi, Valerio Da Ros, Livia Biancone, Alberto Bergamini, Maria Sole Chimenti

Background: Enteropathic spondyloarthritides (eSpAs) are chronic inflammatory joint diseases associated with inflammatory bowel disease (IBD). Limited data are available on the prevalence since arthritis in IBD patients may be underestimated because medications may hide disease activity with a possible diagnostic delay.

Objectives: We aimed to evaluate diagnostic delay in eSpA and explore associated demographic, clinical, and radiographic characteristics.

Design: Single-centre cross-sectional study conducted on consecutive out-patients referred to the combined Gi-Rhe clinic (November 2018-October 2019).

Methods: We analysed eSpA patients for diagnostic delay, disease activity, inflammatory markers, conventional radiography (CR) and magnetic resonance images (MRI) of sacroiliac joints/spine.

Results: A total of 190 eSpA patients [118 peripheral SpA, 72 axial (Ax) SpA including 44 non-radiographic (nr)-axSpA] were enrolled. axSpA patients had a higher prevalence of men sex, HLA-B27 positivity, uveitis and pancolitis compared with peripheral eSpA. Median diagnostic delay in eSpA was 48 months (IQR 6-77) with no difference between axial and peripheral patients. Radiographic-axial SpA (r-axSpA) patients displayed a higher diagnostic delay compared with nr-axSpA (median/IQR 36/17-129 versus 31/10-57 months, p = 0.03) and were older, with longer disease duration, low education status and high rate of employment than patients with nr-axSpA. r-axSpA patients with sclerosis, syndesmophytes and bridge at CR had higher diagnostic delay than those without lesions. Men showed higher prevalence of spine damage lesions than women as sclerosis, squaring, syndesmophytes and bridges. Longer disease duration was detected in patients with radiographic damage as bridge and sacroiliitis grade 3. On MRI, sacroiliac bone oedema was associated with reduced diagnostic delay, whereas bone erosions were associated with higher diagnostic delay compared with that in patients without these lesions. Patients with psoriasis displayed a higher diagnostic delay compared to those without skin involvement.

Conclusion: Diagnostic delay was higher in r-axSpA compared with nr-axSpA despite the same treatment. Demographic, clinical features and radiological lesions were associated with diagnostic delay.

背景:肠病性脊柱关节炎(eSpAs)是与炎症性肠病(IBD)相关的慢性炎症性关节疾病。由于药物可能会掩盖疾病的活动性,从而导致诊断延迟,因此 IBD 患者的关节炎发病率可能会被低估:我们旨在评估 eSpA 的诊断延迟,并探讨相关的人口学、临床和放射学特征:对转诊至吉河联合诊所的连续门诊患者进行单中心横断面研究(2018 年 11 月至 2019 年 10 月):我们分析了eSpA患者的诊断延迟、疾病活动性、炎症标志物、骶髂关节/脊柱的常规放射摄影(CR)和磁共振成像(MRI):与周围性 eSpA 相比,轴性 eSpA 患者中男性、HLA-B27 阳性、葡萄膜炎和胰腺炎的发病率更高。eSpA的中位诊断延迟时间为48个月(IQR 6-77),轴向和外周患者之间没有差异。影像学轴向脊柱关节炎(r-axSpA)患者的诊断延迟时间高于非轴向脊柱关节炎患者(中位数/IQR为36/17-129个月对31/10-57个月,p = 0.03),而且与非轴向脊柱关节炎患者相比,患者年龄更大、病程更长、受教育程度更低且就业率更高。与女性相比,男性脊柱损伤病变的发生率更高,如硬化、方形、联合骨赘和脊柱桥。在骶髂骨桥和骶髂骨炎 3 级放射损伤患者中,病程较长。在核磁共振成像中,骶髂骨水肿与诊断延迟减少有关,而骨侵蚀与诊断延迟增加有关。与没有皮肤受累的患者相比,银屑病患者的诊断延迟率更高:结论:尽管治疗方法相同,但r-axSpA患者的诊断延迟率高于nr-axSpA患者。人口统计学、临床特征和放射学病变与诊断延迟有关。
{"title":"Clinical and imaging findings in enteropathic spondyloarthritis with special emphasize in diagnostic delay: a cross-sectional study.","authors":"Paola Conigliaro, Arianna D'Antonio, Andrea Wlderk, Federico Sabuzi, Mario Ferraioli, Leonardo Sichi, Valerio Da Ros, Livia Biancone, Alberto Bergamini, Maria Sole Chimenti","doi":"10.1177/20406223241229843","DOIUrl":"10.1177/20406223241229843","url":null,"abstract":"<p><strong>Background: </strong>Enteropathic spondyloarthritides (eSpAs) are chronic inflammatory joint diseases associated with inflammatory bowel disease (IBD). Limited data are available on the prevalence since arthritis in IBD patients may be underestimated because medications may hide disease activity with a possible diagnostic delay.</p><p><strong>Objectives: </strong>We aimed to evaluate diagnostic delay in eSpA and explore associated demographic, clinical, and radiographic characteristics.</p><p><strong>Design: </strong>Single-centre cross-sectional study conducted on consecutive out-patients referred to the combined <i>Gi-Rhe</i> clinic (November 2018-October 2019).</p><p><strong>Methods: </strong>We analysed eSpA patients for diagnostic delay, disease activity, inflammatory markers, conventional radiography (CR) and magnetic resonance images (MRI) of sacroiliac joints/spine.</p><p><strong>Results: </strong>A total of 190 eSpA patients [118 peripheral SpA, 72 axial (Ax) SpA including 44 non-radiographic (nr)-axSpA] were enrolled. axSpA patients had a higher prevalence of men sex, HLA-B27 positivity, uveitis and pancolitis compared with peripheral eSpA. Median diagnostic delay in eSpA was 48 months (IQR 6-77) with no difference between axial and peripheral patients. Radiographic-axial SpA (r-axSpA) patients displayed a higher diagnostic delay compared with nr-axSpA (median/IQR 36/17-129 <i>versus</i> 31/10-57 months, <i>p</i> = 0.03) and were older, with longer disease duration, low education status and high rate of employment than patients with nr-axSpA. r-axSpA patients with sclerosis, syndesmophytes and bridge at CR had higher diagnostic delay than those without lesions. Men showed higher prevalence of spine damage lesions than women as sclerosis, squaring, syndesmophytes and bridges. Longer disease duration was detected in patients with radiographic damage as bridge and sacroiliitis grade 3. On MRI, sacroiliac bone oedema was associated with reduced diagnostic delay, whereas bone erosions were associated with higher diagnostic delay compared with that in patients without these lesions. Patients with psoriasis displayed a higher diagnostic delay compared to those without skin involvement.</p><p><strong>Conclusion: </strong>Diagnostic delay was higher in r-axSpA compared with nr-axSpA despite the same treatment. Demographic, clinical features and radiological lesions were associated with diagnostic delay.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241229843"},"PeriodicalIF":3.5,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10878219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of major non-communicable diseases and their associated risk factors in Afghanistan: a systematic review and meta-analysis. 阿富汗主要非传染性疾病及其相关风险因素的流行情况:系统回顾和荟萃分析。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-14 eCollection Date: 2024-01-01 DOI: 10.1177/20406223241229850
Ahmad Siyar Noormal, Volker Winkler, Sneha Bansi Bhusari, Olaf Horstick, Valérie R Louis, Andreas Deckert, Khatia Antia, Zahia Wasko, Pratima Rai, Aline Frare Mocruha, Peter Dambach

Background: Non-communicable diseases (NCDs) are the leading cause of mortality worldwide, and increasingly so in low- and middle-income countries. Afghanistan is dealing with a double burden of diseases, yet there has been no evidence synthesis on the prevalence of major NCDs and their risk factors.

Objective: This study aims to provide a comprehensive synthesis of the existing data on the prevalence of major NCDs and the common related risk factors in Afghanistan.

Method: We systematically reviewed scientific articles from 2000 to 2022 that reported the prevalence of diabetes, chronic respiratory diseases (CRDs), cardiovascular diseases (CVDs) or cancer, and their risk factors in Afghanistan. Four online databases (PubMed, Web of Science, Cochrane and Google Scholar) and two local journals in Afghanistan (not indexed online) were systematically searched and screened. Two reviewers independently screened and appraised the quality of the articles. Data extraction and synthesis were performed using tabulated sheets.

Results: Among 51 eligible articles, 10 (19.6%) focused on cancer, 10 (19.6%) on diabetes, 4 (7.8%) on CVDs, 4 (7.8%) on CRDs and 23 (45.1%) on risk factors as the primary outcome. Few articles addressed major NCD prevalence; no evidence of CVDs, cancer was 0.15%, asthma ranged between 0.3% and 17.3%, and diabetes was 12%. Pooled prevalence of hypertension and overweight were 31% and 35%, respectively. Central obesity was twice as prevalent in females (76% versus 40%). Similarly, gender differences were observed in smoking and snuff use with prevalence rates of 14% and 25% among males and 2% and 3% among females, respectively. A total of 14% of the population engaged in vigorous activity. Pooled prevalence for physical inactivity, general obesity, fruit and vegetable consumption, dyslipidaemia and alcohol consumption couldn't be calculated due to the heterogeneity of articles.

Conclusion: Only little evidence is available on the prevalence of major NCDs in Afghanistan; however, the NCD risk factors are prevalent across the country. The quality of the available data, especially those of the local resources, is poor; therefore, further research should generate reliable evidence in order to inform policymakers on prioritizing interventions for controlling and managing NCDs.

背景:非传染性疾病 (NCD) 是导致全球死亡的主要原因,在低收入和中等收入国家也日益如此。阿富汗正面临着疾病的双重负担,但目前还没有关于主要非传染性疾病的发病率及其风险因素的证据综述:本研究旨在全面综述阿富汗主要非传染性疾病流行率及其常见相关风险因素的现有数据:我们系统地查阅了 2000 年至 2022 年期间报道阿富汗糖尿病、慢性呼吸道疾病 (CRD)、心血管疾病 (CVD) 或癌症及其风险因素患病率的科学文章。对四个在线数据库(PubMed、Web of Science、Cochrane 和 Google Scholar)和两份阿富汗当地期刊(未被在线索引)进行了系统检索和筛选。两名审稿人对文章进行了独立筛选和质量评估。数据提取和综合使用表格进行:在 51 篇符合条件的文章中,10 篇(19.6%)关注癌症,10 篇(19.6%)关注糖尿病,4 篇(7.8%)关注心血管疾病,4 篇(7.8%)关注慢性阻塞性肺疾病,23 篇(45.1%)关注作为主要结果的风险因素。很少有文章涉及主要非传染性疾病的发病率;没有证据表明心血管疾病、癌症的发病率为 0.15%,哮喘的发病率在 0.3% 到 17.3% 之间,糖尿病的发病率为 12%。高血压和超重的汇总患病率分别为 31% 和 35%。女性中心性肥胖的发病率是男性的两倍(76% 对 40%)。同样,在吸烟和使用鼻烟方面也发现了性别差异,男性吸烟率为 14%,女性为 25%,分别为 2%和 3%。共有 14% 的人口从事剧烈运动。由于文章的异质性,无法计算体育锻炼不足、一般肥胖症、水果和蔬菜摄入量、血脂异常和酒精摄入量的综合流行率:关于阿富汗主要非传染性疾病发病率的证据很少;但是,非传染性疾病的风险因素在全国各地都很普遍。现有数据的质量较差,尤其是当地资源的数据;因此,进一步的研究应产生可靠的证据,以便为决策者提供信息,确定控制和管理非传染性疾病的干预措施的优先次序。
{"title":"Prevalence of major non-communicable diseases and their associated risk factors in Afghanistan: a systematic review and meta-analysis.","authors":"Ahmad Siyar Noormal, Volker Winkler, Sneha Bansi Bhusari, Olaf Horstick, Valérie R Louis, Andreas Deckert, Khatia Antia, Zahia Wasko, Pratima Rai, Aline Frare Mocruha, Peter Dambach","doi":"10.1177/20406223241229850","DOIUrl":"10.1177/20406223241229850","url":null,"abstract":"<p><strong>Background: </strong>Non-communicable diseases (NCDs) are the leading cause of mortality worldwide, and increasingly so in low- and middle-income countries. Afghanistan is dealing with a double burden of diseases, yet there has been no evidence synthesis on the prevalence of major NCDs and their risk factors.</p><p><strong>Objective: </strong>This study aims to provide a comprehensive synthesis of the existing data on the prevalence of major NCDs and the common related risk factors in Afghanistan.</p><p><strong>Method: </strong>We systematically reviewed scientific articles from 2000 to 2022 that reported the prevalence of diabetes, chronic respiratory diseases (CRDs), cardiovascular diseases (CVDs) or cancer, and their risk factors in Afghanistan. Four online databases (PubMed, Web of Science, Cochrane and Google Scholar) and two local journals in Afghanistan (not indexed online) were systematically searched and screened. Two reviewers independently screened and appraised the quality of the articles. Data extraction and synthesis were performed using tabulated sheets.</p><p><strong>Results: </strong>Among 51 eligible articles, 10 (19.6%) focused on cancer, 10 (19.6%) on diabetes, 4 (7.8%) on CVDs, 4 (7.8%) on CRDs and 23 (45.1%) on risk factors as the primary outcome. Few articles addressed major NCD prevalence; no evidence of CVDs, cancer was 0.15%, asthma ranged between 0.3% and 17.3%, and diabetes was 12%. Pooled prevalence of hypertension and overweight were 31% and 35%, respectively. Central obesity was twice as prevalent in females (76% <i>versus</i> 40%). Similarly, gender differences were observed in smoking and snuff use with prevalence rates of 14% and 25% among males and 2% and 3% among females, respectively. A total of 14% of the population engaged in vigorous activity. Pooled prevalence for physical inactivity, general obesity, fruit and vegetable consumption, dyslipidaemia and alcohol consumption couldn't be calculated due to the heterogeneity of articles.</p><p><strong>Conclusion: </strong>Only little evidence is available on the prevalence of major NCDs in Afghanistan; however, the NCD risk factors are prevalent across the country. The quality of the available data, especially those of the local resources, is poor; therefore, further research should generate reliable evidence in order to inform policymakers on prioritizing interventions for controlling and managing NCDs.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241229850"},"PeriodicalIF":3.5,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10868487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Advances in Chronic Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1